Sheffield Hallam University and clinical stage pharmaceutical company PharmaKure have entered into a partnership that will focus on gene-based environmental biomarkers, or epigenetic markers, for calculating risk scores for Alzheimer’s diseases (AD). Click to read more.
PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, today announces a new epigenetics collaboration with Sheffield Hallam University. This partnership will focus on ‘gene-based environmental biomarkers’, known as .
PharmaKure announces Alzheimer's epigenetics collaboration with Sheffield Hallam University zenopa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zenopa.com Daily Mail and Mail on Sunday newspapers.